GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biotech company specializing in the treatment of cardiovascular diseases. Its stock price is highly volatile and driven by news about the clinical trials of its lead drug candidate.
Share prices of companies in the market segment - Heart
Milestone Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of episodic cardiovascular diseases, particularly paroxysmal tachycardia. We classify the company in the "Heart Disease" segment, where the speed and effectiveness of drug action are crucial. The chart below shows the dynamics of this important sector.
Broad Market Index - GURU.Markets
Milestone Pharmaceuticals is a biopharmaceutical company that has developed a nasal spray for the treatment of paroxysmal supraventricular tachycardia. As a component of the GURU.Markets index, it represents the cardiology sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
MIST - Daily change in the company's share price Milestone Pharmaceuticals
Change_co for Milestone, a pharmaceutical company, measures its high volatility. It reflects sensitivity to the results of clinical trials of cardiac drugs. This metric is a key element in the formulas on System.GURU.Markets for analyzing the pharmaceutical sector.
Daily change in the price of a set of shares in a market segment - Heart
Milestone Pharmaceuticals Inc. is a pharmaceutical company. This chart highlights the sector's high volatility. Comparing it to MIST, which focuses on cardiovascular disease treatments, helps assess its risk relative to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Milestone Pharmaceuticals is a biotech company specializing in cardiovascular disease treatment. Its shares move in sync with clinical trial news. This high, event-driven volatility feeds into the overall market flow.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Milestone Pharmaceuticals
Milestone Pharmaceuticals' year-end performance is a story about the development of a nasal spray for the treatment of arrhythmia attacks. Its 12-month market capitalization depends entirely on the results of clinical trials and FDA approval. Successful approval could offer patients a convenient and quick way to stop an attack at home.
Annual dynamics of market capitalization of the market segment - Heart
Milestone Pharmaceuticals Inc. is a late-stage biopharmaceutical company developing a nasal spray for the treatment of cardiac arrhythmia. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Milestone is a biopharmaceutical company whose stock performance is driven by the commercialization of its products and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Milestone Pharmaceuticals
Milestone Pharmaceuticals (Heart) is focused on developing cardiac drugs. The Perf_Month_Co chart reflects how clinical trial cycles and safety/efficacy data for experimental drugs impact midterm valuations, being highly sensitive to regulatory milestones and pipeline updates.
Monthly dynamics of market capitalization of the market segment - Heart
This chart reflects the dynamics of the biotech sector, particularly cardiology. For Milestone, a late-stage company, it's the backdrop. Its movements reflect investor expectations surrounding the potential approval of its drug, which could be a major event not only for the company but for the entire niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Milestone Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of cardiovascular diseases, particularly paroxysmal tachycardia. Its value is determined by the results of clinical trials. The overall market price has little bearing on Milestone shares; their price is dependent on scientific news and regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company developing a nasal spray for the treatment of episodes of rapid heartbeat. Its weekly stock price is driven by news about clinical trials and the FDA approval process.
Weekly dynamics of market capitalization of the market segment - Heart
Milestone Pharmaceuticals is developing a drug to treat arrhythmia attacks. It's a highly specialized company whose success depends on a single product. The chart shows how news about clinical trials and regulatory decisions can cause sharp fluctuations in stock prices unrelated to the overall state of the pharmaceutical market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Milestone is a pharmaceutical company whose shares move on news about clinical trials. It's a classic example of an asset that doesn't correlate with the market. The chart clearly demonstrates how much its performance is driven by scientific news rather than general economic trends.
Market capitalization of the company, segment and market as a whole
MIST - Market capitalization of the company Milestone Pharmaceuticals
Milestone Pharmaceuticals' market capitalization dynamics is a chart of a biotech company focused on treating cardiovascular diseases. Its valuation depends on the success of its lead drug candidate in clinical trials. Sharp movements on the chart reflect investors' reactions to any development news.
MIST - Share of the company's market capitalization Milestone Pharmaceuticals within the market segment - Heart
Milestone Pharmaceuticals is a biopharmaceutical company developing a nasal spray for the treatment of palpitations. Its market share currently reflects the product's potential. The company's growth is a bet on offering patients a fast and convenient solution for palpitations.
Market capitalization of the market segment - Heart
Here's a chart showing the market capitalization of the pharmaceutical sector. Milestone Pharmaceuticals specializes in the treatment of paroxysmal supraventricular tachycardia. The company has developed a nasal spray for rapid relief of attacks. Its market history exemplifies how innovation in a narrow niche can create a completely new standard of care for patients.
Market capitalization of all companies included in a broad market index - GURU.Markets
Milestone Pharmaceuticals is developing a nasal spray for the rapid relief of arrhythmia attacks. Its market capitalization is based on the hope of creating a convenient self-help product. The chart below shows the economic weight of companies developing "rescue" medications.
Book value capitalization of the company, segment and market as a whole
MIST - Book value capitalization of the company Milestone Pharmaceuticals
Milestone Pharmaceuticals' foundation is its intellectual property, etryptamyl nasal spray, for the treatment of paroxysmal supraventricular tachycardia. The chart depicts the story of a late-stage biotech company whose book value is derived from the capital required to obtain FDA approval and prepare for commercial launch.
MIST - Share of the company's book capitalization Milestone Pharmaceuticals within the market segment - Heart
Milestone Pharmaceuticals is developing a nasal spray for the treatment of arrhythmia. The chart shows its share of actual R&D assets. These are its laboratories and clinical programs, which provide the material basis for bringing an innovative and patient-friendly drug to market.
Market segment balance sheet capitalization - Heart
Milestone Pharmaceuticals is a biotech company whose value lies in its development pipeline. Its business is capital-light. The chart below reflects the capital intensity of the pharmaceutical sector, highlighting its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Milestone Pharmaceuticals is developing a nasal spray for the treatment of arrhythmia attacks. The company's assets include its R&D. A small stake in BCap_All is a material resource aimed at creating a convenient and fast-acting treatment that can save lives in critical situations.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company. Its premium is a bet on its nasal spray for the treatment of tachycardia attacks, which could become a convenient alternative to hospital visits.
Market to book capitalization ratio in a market segment - Heart
Milestone Pharmaceuticals is a pharmaceutical company specializing in the treatment of cardiovascular diseases. Its value is driven by the potential of its lead drug. This metric represents a significant premium to book value, reflecting investor expectations for success and commercialization.
Market to book capitalization ratio for the market as a whole
Milestone Pharmaceuticals is a biopharmaceutical company developing a spray to treat heart palpitations. Its valuation is based on the potential of a single product. This chart demonstrates how market value in biotech can be detached from book value, reflecting expectations for commercial success.
Debts of the company, segment and market as a whole
MIST - Company debts Milestone Pharmaceuticals
Milestone Pharmaceuticals, a company developing drugs for the treatment of cardiovascular diseases, uses equity to finance its clinical programs. Its debt strategy is aimed at conducting late-stage trials of its lead candidate, which requires significant funds to achieve regulatory approval and subsequent commercialization.
Market segment debts - Heart
Milestone Pharmaceuticals is a biopharmaceutical company developing a nasal spray for the treatment of arrhythmia. Developing such an innovative product requires significant investment in clinical trials. This chart shows the company's financial strategy for commercializing its drug, which could change the standard of care.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on treating cardiovascular diseases. Drug development in this area requires lengthy and expensive clinical trials. This chart shows the company's reliance on debt to finance its R&D, allowing us to assess its financial risk.
Market segment debt to market segment book capitalization - Heart
Milestone Pharmaceuticals is a biopharmaceutical company developing a spray to treat heart palpitations. This chart shows debt trends in their sector. It helps assess how the company is funding its clinical trials and commercialization preparations, and how its debt strategy compares to other players in the cardiac drug market.
Debt to book value of all companies in the market
Milestone Pharmaceuticals is a late-stage biopharmaceutical company developing a drug to treat cardiac arrhythmia. Even at this stage, before generating stable revenue, the company is likely financed by shareholders rather than banks. This graph of total debt in the economy highlights that its financial model relies on regulatory approval rather than leverage.
P/E of the company, segment and market as a whole
P/E - Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company developing a spray for the self-administered treatment of arrhythmia. This chart shows investor expectations for its unique product. The valuation is based on the potential to transform patients' lives and capture a significant niche in the cardiology market.
P/E of the market segment - Heart
This chart for biopharmaceutical companies serves as a benchmark for Milestone Pharmaceuticals. It reflects how investors value the sector on average. Comparisons with this chart help us understand whether Milestone's cardiovascular development, specifically its nasal spray, is viewed as more or less promising than those of other cardiology companies.
P/E of the market as a whole
Milestone Pharmaceuticals is developing a nasal spray for the emergency treatment of paroxysmal supraventricular tachycardia. It's a niche but important product. This chart of overall pharmaceutical industry sentiment helps understand how investors evaluate companies targeting niche markets where convenience and rapid onset of action are paramount.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Milestone Pharmaceuticals
Milestone Pharmaceuticals is a pharmaceutical company developing a nasal spray for the emergency treatment of paroxysmal supraventricular tachycardia (PSVT). This chart shows the expected commercialization of its niche product. The evaluation depends on FDA approval and the company's ability to convince physicians and patients of the benefits of rapid self-treatment.
%20P%2FE%20Milestone%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Milestone-Pharmaceuticals&v=1772593019829 "Chart of the company's future (projected) P/E Milestone Pharmaceuticals")
Future (projected) P/E of the market segment - Heart
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing a nasal spray for the treatment of heart palpitations. This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess the market's perception of the potential of its innovative drug.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772593019848 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
Milestone Pharmaceuticals is a biopharmaceutical company developing a nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). Given the general market expectations shown by this chart, Milestone's business is driven by medical needs and R&D successes, rather than by general economic trends.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772593019862 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Milestone Pharmaceuticals
Milestone Pharmaceuticals is a pharmaceutical company developing an intranasal spray for the emergency treatment of paroxysmal supraventricular tachycardia (PSVT). This chart shows the company's financial status as it moves toward commercialization of its innovative cardiac drug.
Profit of companies in the market segment - Heart
Milestone Pharmaceuticals is developing a nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). This chart shows profitability in the cardiology sector. For MIST, this reflects the need for a fast-acting and convenient treatment for patients suffering from sudden attacks of rapid heartbeat, which could change the standard of care.
Overall market profit
Milestone Pharmaceuticals is a Canadian biopharmaceutical company developing a spray for the self-administered treatment of paroxysmal supraventricular tachycardia (PSVT). This is a niche product for emergency use. The company's success depends on regulatory approval and commercialization. This gross profit chart does not reflect the specifics of the pharmaceutical market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Milestone Pharmaceuticals
Milestone Pharmaceuticals is developing a nasal spray for the emergency treatment of paroxysmal supraventricular tachycardia (PSVT), a common arrhythmia. The revenue projections presented here are contingent on FDA approval and successful market launch. This is a bet on a new, patient-friendly treatment option.
%20profit%20of%20the%20company%20Milestone%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Milestone-Pharmaceuticals&v=1772593020041 "Graph of future (projected) profit of the company Milestone Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Heart
Milestone Pharmaceuticals is developing a nasal spray for the emergency treatment of paroxysmal supraventricular tachycardia (PSVT), a common heart rhythm disorder. The revenue forecast for this segment depends on the approval and adoption of this new approach. This chart reflects analyst expectations regarding the commercial potential of self-help medications.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772593020080 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
Milestone Pharmaceuticals is a biopharmaceutical company specializing in the treatment of cardiovascular diseases. Its value is determined by progress in clinical trials. Market-wide profit forecasts, reflected here, shape the investment climate, which influences the company's ability to attract R&D funds.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772593020095 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Milestone Pharmaceuticals
Milestone Pharmaceuticals is a Canadian biopharmaceutical company developing a spray for emergency relief of heart palpitations. This chart shows a speculative valuation. Investors are assessing the potential market size for this niche product and the likelihood of its approval by regulators and acceptance by physicians.
P/S market segment - Heart
Milestone Pharmaceuticals is a pharmaceutical company developing a nasal spray for the rapid treatment of paroxysmal supraventricular tachycardia (PSVT). This chart reflects the average revenue estimate for the sector, providing insight into how investors view the potential of Milestone's product to address an important medical need.
P/S of the market as a whole
Milestone Pharmaceuticals is a pharmaceutical company developing a nasal spray for the emergency treatment of paroxysmal supraventricular tachycardia, a common type of arrhythmia. The company's success depends on the approval and commercialization of this product. This chart provides a general market backdrop for assessing investor sentiment toward innovative healthcare companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Milestone Pharmaceuticals
Milestone Pharmaceuticals is developing a nasal spray for the emergency treatment of heart palpitations. This chart shows how the market values the company based on its future revenue potential. It reflects hopes that its drug will become a convenient alternative to hospital treatment.
%20P%2FS%20Milestone%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Milestone-Pharmaceuticals&v=1772593020420 "The graph of the company's future (projected) P/S Milestone Pharmaceuticals")
Future (projected) P/S of the market segment - Heart
Milestone Pharmaceuticals is developing a nasal spray for the emergency treatment of paroxysmal supraventricular tachycardia, a common type of arrhythmia. This graph reflects investor expectations regarding the commercial potential of this convenient, fast-acting, and self-administered medication.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772593020547 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
Milestone Pharmaceuticals is a biopharmaceutical company developing a spray to treat heart palpitations. Their success depends on regulatory approval and commercialization. This market optimism curve is important. It impacts the availability of capital to complete clinical trials and the healthcare system's readiness to accept new, even non-lifesaving, drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772593020666 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Milestone Pharmaceuticals
Milestone Pharmaceuticals is a late-stage pharmaceutical company developing a nasal spray for the rapid termination of arrhythmia. Currently, the company's revenue is minimal. This graph will ultimately indicate the commercial success of their drug, should it be approved by regulators and accepted by the medical community.
Sales of companies in the market segment - Heart
Milestone Pharmaceuticals is a biopharmaceutical company developing a new nasal spray for the emergency treatment of paroxysmal supraventricular tachycardia (PSVT), a condition characterized by sudden increases in heart rate. Currently in late-stage clinical development, the company is preparing to commercialize its only product.
Overall market sales
Milestone Pharmaceuticals is a biopharmaceutical company developing a nasal spray for the emergency treatment of paroxysmal supraventricular tachycardia, a common type of arrhythmia. This revenue chart includes the healthcare sector, where MIST aims to offer patients a fast and convenient solution for at-home management of attacks.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Milestone Pharmaceuticals
Milestone Pharmaceuticals is developing a nasal spray for the emergency treatment of paroxysmal supraventricular tachycardia, a common type of arrhythmia. This schedule reflects analysts' expectations for the success of clinical trials and the commercial potential of this patient-friendly drug.
%20sales%20of%20the%20company%20Milestone%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Milestone-Pharmaceuticals&v=1772593021006 "Schedule of future (projected) sales of the company Milestone Pharmaceuticals")
Future (projected) sales of companies in the market segment - Heart
Milestone Pharmaceuticals is a biopharmaceutical company developing a nasal spray for the rapid termination of paroxysmal supraventricular tachycardia (PSVT). This chart shows forecasts for the arrhythmia treatment market. It reflects the need for convenient and fast-acting medications that patients can self-administer.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772593021034 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
Milestone Pharmaceuticals, which focuses on treating cardiovascular diseases, sees this chart as a reflection of the state of the healthcare system. The rising overall economic outlook ensures budget stability for clinics and insurance companies. This is important for the introduction of new drugs for the treatment of tachycardia attacks that Milestone is developing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772593021074 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of cardiovascular diseases. While in clinical trials, it does not generate revenue. This chart shows its capital burn rate—an indicator of how effectively investments are managed on the path to commercialization.
Market segment marginality - Heart
Milestone Pharmaceuticals is a biopharmaceutical company developing a spray for the emergency treatment of palpitations. This indicator reflects the commercial potential of its product. If approved, a high result would indicate a significant unmet need for such a treatment.
Market marginality as a whole
Milestone Pharmaceuticals is a pharmaceutical company focused on cardiovascular treatments. Its success depends on the approval and commercialization of its products. This total revenue chart does not reflect the specifics of the pharmaceutical market, where patents, clinical data, and competition are crucial.
Employees in the company, segment and market as a whole
Number of employees in the company Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company developing a nasal spray for the self-administered treatment of paroxysmal supraventricular tachycardia (PSVT), a common arrhythmia. This graph shows the small team conducting clinical trials of this innovative product.
Share of the company's employees Milestone Pharmaceuticals within the market segment - Heart
Milestone Pharmaceuticals is a biopharmaceutical company developing a nasal spray for the rapid termination of supraventricular tachycardia. Preparing to launch this new drug requires expanding its clinical research and marketing team. This chart demonstrates its potential and growing importance in the field of cardiac pharmacology.
Number of employees in the market segment - Heart
Milestone Pharmaceuticals is developing a nasal spray for the emergency treatment of paroxysmal supraventricular tachycardia (PSVT), a common arrhythmia. This graphic shows a focused team working to empower patients to quickly and independently terminate the attack, avoiding trips to the emergency room.
Number of employees in the market as a whole
Milestone Pharmaceuticals is a company developing drugs to treat cardiovascular diseases. The economic environment, reflected in the employment graph, indirectly impacts their success. Stable employment provides patients with access to health insurance, which guarantees future demand for the new and more effective treatments Milestone is developing.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals is a pharmaceutical company focused on cardiovascular drugs. This chart reflects a business in the commercialization stage. The company's capitalization per employee will be lower than that of a pure R&D biotech company, as the company requires a staff of sales and marketing specialists to promote its product to doctors.
%20of%20the%20company%20Milestone%20Pharmaceuticals%20(MIST)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Milestone-Pharmaceuticals-MIST&v=1772593021765 "Chart of market capitalization per employee (in thousands of dollars) of the company Milestone Pharmaceuticals (MIST)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of cardiovascular diseases. Its value is determined by progress in clinical trials. This chart reflects investor expectations for its developments, showing the market valuation per employee compared to other biotech companies.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772593021826 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
Milestone Pharmaceuticals is a biopharmaceutical company developing a nasal spray for the treatment of arrhythmia attacks. In this niche, this indicator reflects the potential of its core product. It shows how the market perceives the convenience and effectiveness of a medication that patients can self-administer for rapid relief of attacks.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772593022115 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals is a clinical-stage biotech company developing a spray for the treatment of arrhythmia (SVT). This graph is negative. The company is in the R&D phase and is preparing to submit an application to the FDA. There is no profit; the entire staff is focused on completing clinical trials and regulatory processes.
%20Chart%20Milestone%20Pharmaceuticals%20(MIST)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Milestone-Pharmaceuticals-MIST&v=1772593022206 "Company Profit Per Employee (in thousands of dollars) Chart Milestone Pharmaceuticals (MIST)")
Profit per employee (in thousands of dollars) in the market segment - Heart
Milestone Pharmaceuticals is a pharmaceutical company developing Etripamil, a nasal spray for the self-treatment of paroxysmal supraventricular tachycardia (rapid heartbeat). This chart shows the industry benchmark, serving as a benchmark for profitability achieved in the pharmaceutical industry. For Milestone, it contrasts with the current R&D costs to bring this innovative "cardio-spray" to market.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772593022272 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
Milestone Pharmaceuticals is a biotech company focused on treating cardiac arrhythmia. Their lead product is the nasal spray Etripamil, designed for at-home self-management of arrhythmia. This is a late-stage R&D company. This graph shows the investment (negative profit) per employee required to approve and bring this innovative product to market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772593022348 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals is a biopharmaceutical company developing a spray for the treatment of tachycardia attacks. This graph illustrates the company's path from clinical trials to market. The potential increase in revenue per employee after product approval will indicate the demand for its innovative and patient-friendly solution.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Milestone-Pharmaceuticals-MIST&v=1772593022364 "Sales chart per company employee Milestone Pharmaceuticals (MIST)")
Sales per employee in the market segment - Heart
Milestone Pharmaceuticals (MIST) is a biotech focused on treating arrhythmia. Their main product is a nasal spray (etripamil). They are in late-stage R&D. This chart shows how effective their team (scientists and clinicians) is at generating revenue (which they don't yet have) per employee compared to the industry.
Sales per employee for the market as a whole
Milestone Pharmaceuticals is a biotech company focused on developing cardiovascular drugs, specifically a nasal spray for the treatment of arrhythmia. This is an R&D business. This graph will likely show zero revenue, as their team is in late-stage trials.
Short shares by company, segment and market as a whole
Shares shorted by company Milestone Pharmaceuticals (MIST)
Milestone (MIST) is a pharmaceutical company developing the nasal spray Etripamil for the emergency treatment of paroxysmal supraventricular tachycardia (PSVT)—attacks of rapid heartbeat. This chart shows bearish bets. The rise in shorts may reflect investor doubts about the market potential of this niche drug or the success of its commercial launch.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Milestone-Pharmaceuticals-MIST&v=1772593022635 "Short Shares Chart for the Company Milestone Pharmaceuticals (MIST)")
Shares shorted by market segment - Heart
Milestone (MIST) is a pharmaceutical company developing a nasal spray (Etripamil) for the emergency treatment of arrhythmia (paroxysmal supraventricular tachycardia). This chart reflects the overall sentiment in the pharmaceutical sector. It shows how many investors doubt the commercial success of their niche drug.
Shares shorted by the overall market
Milestone Pharma (MIST) is developing a nasal spray to treat cardiac arrhythmia. While this is an important market, MIST is a company without stable profits. When this fear indicator rises, investors sell their "stories." They fear that during a recession, the company will have difficulty funding the expensive launch of a new drug.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Milestone Pharmaceuticals (MIST)
Milestone Pharmaceuticals is a biotech whose fate hinges on a single drug—a nasal spray for the treatment of arrhythmia. It's a binary bet: "Will the FDA approve?" This chart measures the extremes of these expectations. It shows when the stock is "overbought" on hope or "oversold" on despair.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Milestone-Pharmaceuticals-MIST&v=1772593022805 "RSI 14 indicator chart for the company's stock Milestone Pharmaceuticals (MIST)")
RSI 14 Market Segment - Heart
Milestone Pharmaceuticals is a biopharmaceutical company specializing in the treatment of tachycardiac attacks (TACA). They developed Etripamil, a nasal spray for self-administered treatment of attacks. This chart measures the overall momentum in the cardiac pharmacology sector. It helps assess whether this entire niche segment is overheated.
RSI 14 for the overall market
Milestone Pharma (MIST) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MIST (Milestone Pharmaceuticals)
Milestone (MIST) is a biopharmaceutical company developing a nasal spray for the treatment of tachycardia (rapid heartbeat). This chart shows the average 12-month forecast. It reflects analysts' confidence in the drug's approval and its potential to fill a niche in the cardiac emergency care market.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MIST-Milestone-Pharmaceuticals&v=1772593023093 "A chart showing analyst consensus forecasts for the expected stock price. MIST (Milestone Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price MIST (Milestone Pharmaceuticals)
Milestone Pharmaceuticals is developing a nasal spray (etripamil) for the emergency termination of tachycardia (ETP) in the community. This chart shows the upside and downside potential analysts see for the stock. It measures the gap between the price and the forecast, reflecting their confidence in the approval and commercial success of this niche drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MIST-Milestone-Pharmaceuticals&v=1772593023157 "A chart showing the difference between the consensus forecast and the actual stock price. MIST (Milestone Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Heart
Milestone Pharma is a biotech company attempting to create a new market: a nasal spray (Etripamil) for the emergency at-home treatment of arrhythmia. This chart shows analysts' overall expectations for the entire cardiac pharmaceutical sector. It reflects whether experts believe in the commercial potential of new approaches to cardiac treatment or consider the market too conservative.
Analysts' consensus forecast for the overall market share price
Milestone Pharmaceuticals is a biopharmaceutical company specializing in the treatment of cardiovascular diseases. Their signature product is a nasal spray for rapidly stopping arrhythmia attacks. This chart shows overall market sentiment. For Milestone, which is launching a niche drug, it's important to understand how these expectations (healthcare budgets) influence its adoption. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biotech company whose fate is tied to a single product: etripamil. It's a nasal spray designed for self-administered arrhythmia treatment (SART) at home, eliminating the need for a hospital visit. This chart summarizes their commercial trajectory. It reflects their progress toward FDA approval and the market's assessment of the potential of this innovative drug.
AKIMA Market Segment Index - Heart
Milestone Pharmaceuticals is developing a nasal spray (Etripamil) for the emergency treatment of arrhythmia (ETA) in the community. It is a highly specialized business. This chart shows the average index for the cardiac segment. It allows investors to assess how Milestone's drug compares to the sector average based on a combination of factors.
The AKIM Index for the overall market
Milestone Pharmaceuticals is a biopharmaceutical company developing treatments for cardiovascular diseases (tachycardia). Its key asset is Etripamil. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is approaching commercialization, fits within the context of overall economic trends.
